Genprex Inc. (GNPX) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Genprex Inc. (NASDAQ: GNPX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $2.04 (+1.49% 1D, market cap $1.7M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, GNPX ranks #365 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GNPX carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OGEN (Oragenics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $1.7M) and PPBT (Purple Biotech Ltd.) posts a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $1.8M). Among the 5-stock peer group, GNPX leads on earnings multiple (N/A) while GNPX leads on capital efficiency (-35.0% ROIC).
Per GNPX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001595248), Genprex Inc. generated $0 in revenue, -$16.2M in net income, and -$15.3M in free cash flow against $10.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 41.5 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±12.5% realized swing band)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While GNPX currently carries a cautious 47/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.97) and Max Pain ($2.14) forces dealer call-delta covering toward $145.53.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Genprex Inc. (GNPX) advanced +1.49% to $2.04, trading at 2% of its 52-week range ($1.71 – $138.6). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabet
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabet
Collaborators publish new peer-reviewed study identifying sex-specific effects of TUSC2 loss on mitochondrial function, protein homeostasis, and synaptic pathways, alongside molecular similarities with human
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on GNPX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for GNPX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Genprex Inc. (GNPX) ranks #365 by composite RQD confidence (47/100, grade D) and #1007 by equity capitalization ($1.7M). Within this direct 5-issuer industry benchmark cohort, GNPX leads on earnings valuation at N/A trailing P/E, while GNPX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PPBT currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with GNPX at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| GNPX
ACTIVE
Genprex Inc. | D | 47/100 | — | — | -35.0% | +1.49% | $1.7M | Benchmark Subject |
| OGEN Oragenics Inc. | D | 44/100 | — | — | -35.0% | -1.53% | $1.7M | /ogen-vs-gnpx → |
| PPBT Purple Biotech Ltd. | C- | 61/100 | — | — | — | +13.86% | $1.8M | /ppbt-vs-gnpx → |
| KAPA Kairos Pharma Ltd. | D- | 37/100 | — | — | -35.0% | +3.25% | $1.8M | /kapa-vs-gnpx → |
| MTNB Matinas Biopharma Holdings Inc. | D- | 35/100 | — | — | -35.0% | -0.52% | $1.9M | /mtnb-vs-gnpx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Genprex Inc. (GNPX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$16.2M, operating cash flow of -$15.3M, and free cash flow of -$15.3M (+14.6% YoY). On the balance sheet, GNPX closed FY2025 with $10.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$16.2M | -$15.3M | -$15.3M | $10.2M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$21.4M | -$17.9M | -$17.9M | $4.1M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$30.9M | -$24.7M | -$24.7M | — | — |
As of 2026-11-02, Genprex Inc. (NASDAQ: GNPX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $2.04 (+1.49% 1D, market cap $1.7M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, GNPX ranks #365 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GNPX carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OGEN (Oragenics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $1.7M) and PPBT (Purple Biotech Ltd.) posts a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $1.8M). Among the 5-stock peer group, GNPX leads on earnings multiple (N/A) while GNPX leads on capital efficiency (-35.0% ROIC).
Per GNPX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001595248), Genprex Inc. generated $0 in revenue, -$16.2M in net income, and -$15.3M in free cash flow against $10.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
GNPX last traded at $2.04 (+1.49% on volume of 155,278 shares), positioning the stock -31.31% below its 50-day simple moving average ($2.97) and -90.01% below its 200-day simple moving average ($20.43). Across its 52-week range of $1.71 to $138.60, GNPX sits at the 0.2% percentile with a 14-day RSI of 41.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.78 to $2.30).
Why GNPX Stock advanced +1.49% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).